Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 20;20(6):1406.
doi: 10.3390/ijms20061406.

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

Reina Sasaki  1 , Tatsuo Kanda  2 , Osamu Yokosuka  3 , Naoya Kato  4 , Shunichi Matsuoka  5 , Mitsuhiko Moriyama  6
Affiliations
Review

Exosomes and Hepatocellular Carcinoma: From Bench to Bedside

Reina Sasaki et al. Int J Mol Sci. .

Abstract

As hepatocellular carcinoma (HCC) usually occurs in the background of cirrhosis, which is an end-stage form of liver diseases, treatment options for advanced HCC are limited, due to poor liver function. The exosome is a nanometer-sized membrane vesicle structure that originates from the endosome. Exosome-mediated transfer of proteins, DNAs and various forms of RNA, such as microRNA (miRNA), long noncoding RNA (lncRNA) and messenger RNA (mRNA), contributes to the development of HCC. Exosomes mediate communication between both HCC and non-HCC cells involved in tumor-associated cells, and several molecules are implicated in exosome biogenesis. Exosomes may be potential diagnostic biomarkers for early-stage HCC. Exosomal proteins, miRNAs and lncRNAs could provide new biomarker information for HCC. Exosomes are also potential targets for the treatment of HCC. Notably, further efforts are required in this field. We reviewed recent literature and demonstrated how useful exosomes are for diagnosing patients with HCC, treating patients with HCC and predicting the prognosis of HCC patients.

Keywords: exosome; hepatocellular carcinoma; long noncoding RNA; microRNA.

PubMed Disclaimer

Conflict of interest statement

T.K. received research grants from AbbVie, Eisai, Daiichi-Sankyo, Shionogi, Mitsubishi-Tanabe Pharma, Astellas, Ono Pharma and Takeda Pharma. The other authors declare no conflict of interest. N.K. reports grants and other from Abbvie, grants and other from Merck & Co., Inc., grants and other from Chugai Pharmaceutical CO., LTD., grants and other from Mitsubishi Tanabe Pharma, grants and other from Gilead Sciences, grants and other from Bristol-Myers Squibb. outside the submitted work. The funders had no role in the designing the study in the collecting, analyzing, or interpreting the data; in writing of the manuscript, or in deciding to publish the results. Other authors declare no conflicts of interest related to this publication.

Figures

Figure 1
Figure 1
Exosomes and hepatocellular carcinoma (HCC). Exosomes transfer proteins, DNAs and various forms of RNA, such as microRNA (miRNA), long noncoding RNA (lncRNA) and messenger RNA (mRNA), between HCC and non-HCC cells. Exosomes induce local and systemic reactions, contributing to the development of HCC. Exosomes are useful biomarkers and therapeutic tools for HCC.
See this image and copyright information in PMC

References

    1. Muhsin-Sharafaldine M.R., Saunderson S.C., Dunn A.C., Faed J.M., Kleffmann T., McLellan A.D. Procoagulant and immunogenic properties of melanoma exosomes, microvesicles and apoptotic vesicles. Oncotarget. 2016;7:56279–56294. doi: 10.18632/oncotarget.10783. - DOI - PMC - PubMed
    1. De Toro J., Herschlik L., Waldner C., Mongini C. Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. Front. Immunol. 2015;6:203. doi: 10.3389/fimmu.2015.00203. - DOI - PMC - PubMed
    1. Philley J.V., Kannan A., Griffith D.E., Devine M.S., Benwill J.L., Wallace R.J., Brown-Elliott B.A., Thakkar F., Taskar V., Fox J.G., et al. Exosome secretome and mediated signaling in breast cancer patients with nontuberculous mycobacterial disease. Oncotarget. 2017;8:18070–18081. doi: 10.18632/oncotarget.14964. - DOI - PMC - PubMed
    1. Riancho J., Vázquez-Higuera J.L., Pozueta A., Lage C., Kazimierczak M., Bravo M., Calero M., Gonalezález A., Rodríguez E., Lleó A., et al. MicroRNA Profile in Patients with Alzheimer’s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. J. Alzheimers. Dis. 2017;57:483–491. doi: 10.3233/JAD-161179. - DOI - PubMed
    1. Zhang Y., Hu Y.-W., Zheng L., Wang Q. Characteristics and Roles of Exosomes in Cardiovascular Disease. DNA Cell Biol. 2017;36:202–211. doi: 10.1089/dna.2016.3496. - DOI - PubMed